Open-label phase 2 trial in 30 US adults (flavivirus seronegative or dengue seropositive): two doses of TAK-003 induced neutralising antibodies against all four dengue serotypes by day 30, sustained for 12 months, with durable T cell responses.
RCTn = 30
Mandaric et al. Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial